COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01465906
Recruitment Status : Unknown
Verified November 2011 by Chunxue Bai, Shanghai Zhongshan Hospital.
Recruitment status was:  Active, not recruiting
First Posted : November 6, 2011
Last Update Posted : November 9, 2011
Information provided by (Responsible Party):
Chunxue Bai, Shanghai Zhongshan Hospital

Brief Summary:

Phrase: IV

Indication: dyspnea symptom of chronic obstructive pulmonary disease (COPD)

Objective: to evaluate efficacy and safety of tulobuterol patch combined with Tiotropium bromide for relieving dyspnea symptom of COPD

Design: a multi-centre randomized parallel blank control study

Case number: test group 80, control group 80, totally 160

Site number:7

Study period: 2010.9 - 2011.8

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: tulobuterol Drug: Tiotropium Bromide Drug: tiotropium bromide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2010
Estimated Primary Completion Date : November 2011
Estimated Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: tulobuterol combined with tiotropium bromide Drug: tulobuterol
patch, 2mg, qN, 3 months

Drug: tiotropium bromide
18ug, inhale, qD, 3 months

Active Comparator: Tiotropium bromide Drug: Tiotropium Bromide
18ug, inhale, qD, 3 months

Primary Outcome Measures :
  1. PFT values (pulmonary function test, see description below) [ Time Frame: 3 months ]
    IC (inspiratory capacity) 、PEF (peak expiratory flow)、FVC (forced vital capacity)、FEV1 (forced expiratory volume in the first second)、%FEV1 (forced expiratory volume in the first second as predicted)、RV (residual volume)、TLC (total lung capacity)、RV/TLC% (residual volume/total lung capacity as percentage), etc.

  2. MRC (Medical Research Council) grade [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. SGRQ (St. George's questionnaire) score [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • people aging from 40 to 80 with self ability of judgment
  • out-patients diagnosed as stable COPD according to "diagnosing and treatment guideline of COPD (2007 edition)" by Respiratory Department of Chinese Medical Association
  • PFT value at screen phase meet the standard as follows: FEV1/FVC < 70% and FEV1% among 30%-80% 15 mins after inhalation of 400ug Ventolin (i.e., moderate and severe COPD patients ).
  • people who can use Tiotropium Bromide powder inhalation device
  • people who join the study voluntarily and sign ICF (Informed Consent Form)

Exclusion Criteria:

  • people who have other acute or chronic respiratory diseases which may cause impairment of pulmonary function such as asthma
  • AECOPD (acute exacerbation of COPD)
  • people who got respiratory failure 1 month before the study
  • people who received oral corticoid treatment 1 month before the study
  • people who undergo oxygen therapy at home because of respiratory failure
  • people who are allergic to β2 receptor agonist such as tulobuterol
  • patients with Skin diseases such as atopic dermatitis, who are not appropriate to use transdermal patch
  • patients of hyperthyroidism, hypertension, heart disease and severe arrhythmia, diabetes mellitus, who are not appropriate to useβ2 receptor agonist
  • patients who have undergone pulmonary lobectomy or have tumor
  • active tuberculosis patients
  • people who got acute respiratory tract infection in a month or during screening phase
  • allergic rhinitis patients
  • glaucoma patients
  • people who have diseases which may cause dysuria such as prostatic hypertrophy or bladder neck occlusion
  • gestation, lactation and child-bearing age women who don't agree to take contraceptive measures during the study
  • people with abnormal live or kidney function, people with nervous system diseases, malignant tumor, neutropenia or other progressive basic diseases.
  • People who are mental retardation, mentally ill, deaf-mute or uncooperative, who cannot correctly describe their disease or do corresponding respiratory questionnaire.
  • People who are allergic to atropine and its derivatives (including tiotropium bromide and ipratropium bromide), lactose or any inhalant components.
  • people who have taken part in other medical clinical trial
  • other conditions that investigators think not appropriate for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01465906

Layout table for location information
China, Shanghai
Zhongshan Hospital, Fudan University
Shanghai, Shanghai, China, 200032
Sponsors and Collaborators
Shanghai Zhongshan Hospital
Layout table for investigator information
Principal Investigator: Chunxue Bai, doctor Fudan University
Layout table for additonal information
Responsible Party: Chunxue Bai, Director of Respiratory Department , Shanghai Zhongshan Hospita, Shanghai Zhongshan Hospital Identifier: NCT01465906    
Other Study ID Numbers: TG1015TLT
First Posted: November 6, 2011    Key Record Dates
Last Update Posted: November 9, 2011
Last Verified: November 2011
Keywords provided by Chunxue Bai, Shanghai Zhongshan Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents